Search Results 1771-1780 of 17027 for monoclonal antibody
Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies, anti-PD1, and anti-PD-L1 therapeutic antibody ...
Synthesis and evaluation of anti-PD-L1-B11 antibody fragments for PET imaging of PD-L1 in breast cancer and melanoma tumor models. Sci Rep. 2024 Aug 22; 14 ...
The vaccine works by causing the body to produce its own protection (antibodies) against these diseases. This vaccine is given only to children 4 to 6 years ...
Mayo Clinic's test is a single evaluation that incorporates both antibodies commonly associated with NAM — HMGCR-IgG and SRP-IgG. The detection of SRP-IgG ...
... antibody less than 4 weeks before the first dose of AG-270. A minimum 2-week period between the last treatment with a therapeutic antibody; and the first ...
UP-NEXT is a double-blind, randomized, placebo controlled study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an ...
... antibodies and the factors that may determine disease progression and treatment response. Spinal Cord Stimulation to Treat Chemotherapy-Induced Peripheral ...
Individuals who had no known COVID-19 exposure (for controls) or had PCR or antibody confirmed COVID-19 who present with neurological symptoms in the months ...
... antibody (HCVAb), and human immunodeficiency virus (HIV) antibody at the Screening Visit or documented in the medical chart within the last 1 year;; Subjects ...
... antibodies). New onset or signs and symptoms of any form of ... Prior exposure to any anti-IgE antibody therapy other than omalizumab and ligelizumab.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.